Wada Naoki, Watanabe Masaki, Kita Masafumi, Matsumoto Seiji, Osanai Hiroaki, Yamaguchi Satoshi, Numata Atsushi, Fujisawa Makoto, Saga Yuji, Hou Kyokushin, Iuchi Hiromitsu, Niibori Daisuke, Kura Tatsuhiko, Taniguchi Akihisa, Kunieda Manabu, Nakata Yasunobu, Kakizaki Hidehiro
Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan. nwada @ asahikawa-med.ac.jp
Urol Int. 2012;89(2):215-21. doi: 10.1159/000339750. Epub 2012 Jul 25.
To evaluate the efficacy of imidafenacin on nocturia and sleep disorder in patients with overactive bladder (OAB).
A prospective multicenter study of imidafenacin 0.1 mg twice daily for patients with OAB and nocturia was conducted. At baseline and at week 4 and 8, patients were assessed using the overactive bladder symptom score (OABSS), frequency volume charts (FVC) and the Pittsburgh Sleep Quality Index (PSQI).
Treatment with imidafenacin significantly improved OAB symptoms. Imidafenacin also improved PSQI, especially subjective sleep quality, sleep latency and daytime dysfunction. In FVC, the number of daytime voids and nighttime voids significantly decreased and average voided volume significantly increased after imidafenacin. Subanalysis of FVC based on the patients' age revealed that nocturnal polyuria was more often found in patients aged 75 years or over than in those aged under 75 years (79 vs. 55%, p < 0.05). Treatment with imidafenacin significantly reduced the nocturnal polyuria index only in patients aged 75 years or over.
Imidafenacin can improve nocturia and sleep disorder in patients with OAB. The efficacy of imidafenacin on nocturia is attributable to an increase in bladder capacity and a decrease in nocturnal urine volume. We conclude that imidafenacin is an effective and safe drug for nocturia in patients with OAB.
评估咪达那新对膀胱过度活动症（OAB）患者夜尿症和睡眠障碍的疗效。
对OAB伴夜尿症患者进行一项前瞻性多中心研究，患者每日两次服用0.1毫克咪达那新。在基线期、第4周和第8周时，使用膀胱过度活动症症状评分（OABSS）、频率 - 尿量图表（FVC）和匹兹堡睡眠质量指数（PSQI）对患者进行评估。
咪达那新治疗显著改善了OAB症状。咪达那新还改善了PSQI，尤其是主观睡眠质量、入睡潜伏期和日间功能障碍。在FVC方面，服用咪达那新后，白天排尿次数和夜间排尿次数显著减少，平均排尿量显著增加。基于患者年龄对FVC进行亚分析显示，75岁及以上患者夜间多尿的发生率高于75岁以下患者（79% 对55%，p < 0.05）。咪达那新治疗仅在75岁及以上患者中显著降低了夜间多尿指数。
咪达那新可改善OAB患者的夜尿症和睡眠障碍。咪达那新对夜尿症的疗效归因于膀胱容量增加和夜间尿量减少。我们得出结论，咪达那新是治疗OAB患者夜尿症的一种有效且安全的药物。
